Investor Director with extensive business development and partnering experience.
Alan Lamont

After initially pursuing a career in science, first in academia then in biotech and pharma companies in the U.K and U.S.A., Dr. Alan Lamont has been engaged in Corporate and Business Development roles for various companies over the past 18 years, including Acambis (UK/US), AstraZeneca (UK), Eli Lilly (UK/US) and latterly with Mundipharma International Ltd. based in Cambridge, UK. During this time, he has executed deals and established partnerships with a large number of external partners, ranging in type from early, pre-clinical stage, R&D collaborative partnerships, in-licensing/acquisition of clinical stage programmes, through to commercial deals involving on-market products. In his roles at Acambis and Mundipharma, he has also gained significant experience in corporate M&A.